SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-16-567037
Filing Date
2016-04-29
Accepted
2016-04-29 11:05:04
Documents
7
Period of Report
2016-06-14
Effectiveness Date
2016-04-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A d166833ddef14a.htm DEF 14A 1272017
2 GRAPHIC g166833g09i54.jpg GRAPHIC 26477
3 GRAPHIC g166833g23a19.jpg GRAPHIC 45367
4 GRAPHIC g166833g25b38.jpg GRAPHIC 8622
5 GRAPHIC g166833g28e77.jpg GRAPHIC 7286
6 GRAPHIC g166833g45x09.jpg GRAPHIC 12263
7 GRAPHIC g166833g71f36.jpg GRAPHIC 40722
  Complete submission text file 0001193125-16-567037.txt   1467820
Mailing Address 2150 ST. ELZEAR BLVD. WEST LAVAL QUEBEC A8 H7L 4A8
Business Address 2150 ST. ELZEAR BLVD. WEST LAVAL QUEBEC A8 H7L 4A8 514-744-6792
Valeant Pharmaceuticals International, Inc. (Filer) CIK: 0000885590 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A8 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-14956 | Film No.: 161603600
SIC: 2834 Pharmaceutical Preparations